Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

In this paper, we introduce a data processing pipeline for cardiogenic shock (CS) prediction from the MIMIC III database of intensive cardiac care unit patients with acute coronary syndrome. The ...

KL4 Surfactant is under clinical development by Windtree Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Most of the change in stage of cardiogenic shock (CS) occurred within the first 24 hours of presentation ... but those with cardiac arrest were on less vasoactive drugs overall. Survivors in stages C, ...

The US Food and Drug Administration (FDA ... patients with acute decompensated heart failure (ADHF) and cardiogenic shock. The amendment of PMA specifies the use of the devices for paediatric ...

Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...